T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study

Gruppo Italiano Mammella (GIM) study group

doi:10.1016/j.clbc.2019.09.001

T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study

Gruppo Italiano Mammella (GIM) study group

Research output: Contribution to journal › Article › peer-review

Abstract

We evaluated efficacy and activity of second-line T-DM1 in 77 patients with human epidermal growth factor receptor 2-positive metastatic breast cancer progressing on front-line pertuzumab-based therapy. The median progression-free survival was inferior as compared with that in the EMILIA trial, which enrolled patients not treated with previous pertuzumab. However, about one-third of patients experienced objective response and durable disease control, suggesting T-DM1 should be considered a valuable option after pertuzumab.

Original language	English
Pages (from-to)	e181-e187
Journal	Clinical Breast Cancer
Volume	20
Issue number	2
DOIs	https://doi.org/10.1016/j.clbc.2019.09.001
Publication status	Published - Apr 2020
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Advanced breast cancer
Prospective study
Real world evidence
Trastuzumab emtansine

Access to Document

10.1016/j.clbc.2019.09.001

Cite this

@article{1aef025a961348ada6a728e68d0527ac,

title = "T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study",

abstract = "We evaluated efficacy and activity of second-line T-DM1 in 77 patients with human epidermal growth factor receptor 2-positive metastatic breast cancer progressing on front-line pertuzumab-based therapy. The median progression-free survival was inferior as compared with that in the EMILIA trial, which enrolled patients not treated with previous pertuzumab. However, about one-third of patients experienced objective response and durable disease control, suggesting T-DM1 should be considered a valuable option after pertuzumab.",

keywords = "Advanced breast cancer, Prospective study, Real world evidence, Trastuzumab emtansine",

author = "\{Gruppo Italiano Mammella (GIM) study group\} and Benedetta Conte and Alessandra Fabi and Francesca Poggio and Eva Blondeaux and Chiara Dellepiane and Alessia D'Alonzo and Giuseppe Buono and Grazia Arpino and Valentina Magri and Giuseppe Naso and Daniele Presti and Silvia Mura and Andrea Fontana and Francesco Cognetti and Chiara Molinelli and Simona Pastorino and Claudia Bighin and Loredana Miglietta and Francesco Boccardo and Matteo Lambertini and \{Del Mastro\}, Lucia",

note = "Publisher Copyright: {\textcopyright} 2019",

year = "2020",

month = apr,

doi = "10.1016/j.clbc.2019.09.001",

language = "English",

volume = "20",

pages = "e181--e187",

journal = "Clinical Breast Cancer",

issn = "1526-8209",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab

T2 - An Italian Multicenter Observational Study

AU - Gruppo Italiano Mammella (GIM) study group

AU - Conte, Benedetta

AU - Fabi, Alessandra

AU - Poggio, Francesca

AU - Blondeaux, Eva

AU - Dellepiane, Chiara

AU - D'Alonzo, Alessia

AU - Buono, Giuseppe

AU - Arpino, Grazia

AU - Magri, Valentina

AU - Naso, Giuseppe

AU - Presti, Daniele

AU - Mura, Silvia

AU - Fontana, Andrea

AU - Cognetti, Francesco

AU - Molinelli, Chiara

AU - Pastorino, Simona

AU - Bighin, Claudia

AU - Miglietta, Loredana

AU - Boccardo, Francesco

AU - Lambertini, Matteo

AU - Del Mastro, Lucia

PY - 2020/4

Y1 - 2020/4

N2 - We evaluated efficacy and activity of second-line T-DM1 in 77 patients with human epidermal growth factor receptor 2-positive metastatic breast cancer progressing on front-line pertuzumab-based therapy. The median progression-free survival was inferior as compared with that in the EMILIA trial, which enrolled patients not treated with previous pertuzumab. However, about one-third of patients experienced objective response and durable disease control, suggesting T-DM1 should be considered a valuable option after pertuzumab.

AB - We evaluated efficacy and activity of second-line T-DM1 in 77 patients with human epidermal growth factor receptor 2-positive metastatic breast cancer progressing on front-line pertuzumab-based therapy. The median progression-free survival was inferior as compared with that in the EMILIA trial, which enrolled patients not treated with previous pertuzumab. However, about one-third of patients experienced objective response and durable disease control, suggesting T-DM1 should be considered a valuable option after pertuzumab.

KW - Advanced breast cancer

KW - Prospective study

KW - Real world evidence

KW - Trastuzumab emtansine

UR - https://www.scopus.com/pages/publications/85082460205

U2 - 10.1016/j.clbc.2019.09.001

DO - 10.1016/j.clbc.2019.09.001

M3 - Article

SN - 1526-8209

VL - 20

SP - e181-e187

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

IS - 2

ER -

T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study

Abstract

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this